암 유전자 치료 시장 규모, 점유율, 성장 분석 : 유형별, 치료법별, 제품 유형별, 최종 용도별, 지역별 - 업계 예측(2026-2033년)

Global Cancer Gene Therapy Market size was valued at USD 4.25 Billion in 2024 and is poised to grow from USD 5.16 Billion in 2025 to USD 24.34 Billion by 2033, growing at a CAGR of 21.4% during the forecast period (2026-2033).

The surge in global cancer incidence is a primary catalyst for the growth of the cancer gene therapy market. The increasing demand for innovative cancer treatments, coupled with advancements in genetic engineering and substantial investments in new therapies, is expected to significantly boost market demand. Ongoing progress in gene technologies and heightened research into their oncology applications are encouraging companies to create groundbreaking cancer gene therapies. Furthermore, the rising preference for personalized cancer treatments aimed at improving survival rates, along with supportive government funding for cancer patients, is anticipated to open up new opportunities for providers in this sector. However, challenges such as high treatment costs, potential adverse reactions, and manufacturing complexities could hinder the long-term development of the cancer gene therapy market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Gene Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Gene Therapy Market Segments Analysis

Global Cancer Gene Therapy Market is segmented by Type, Therapy, Product, End Use and region. Based on Type, the market is segmented into Ex-Vivo and In-Vivo. Based on Therapy, the market is segmented into Oncolytic Virotherapy, Gene-Induced Immunotherapy and Gene Transfer. Based on Product, the market is segmented into Viral Vectors, Non-Viral Vectors and Other Products. Based on End Use, the market is segmented into Biopharma Companies, Research Institutes and Other End-Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Cancer Gene Therapy Market

The Global Cancer Gene Therapy market is experiencing significant growth, largely fueled by advancements in genetic engineering and genome mapping technologies, which have benefited from substantial investments in gene research initiatives. These innovative developments in genetics are increasingly being incorporated into oncology research, leading to the creation of groundbreaking cancer gene therapies. This integration not only enhances the effectiveness of cancer treatments but also broadens the therapeutic options available to patients, ultimately propelling the market forward. As research continues to evolve, the potential for new and improved gene therapies in the fight against cancer remains promising.

Restraints in the Global Cancer Gene Therapy Market

One significant challenge facing the Global Cancer Gene Therapy market is the high cost associated with these advanced treatments, which often makes them inaccessible for many patients. The intricacy of the technology involved and the considerable investment required for development contribute to these elevated expenses. Consequently, the financial barrier limits the widespread adoption of cancer gene therapy, as not all patients can afford these innovative options. This affordability issue hampers the progress of integrating gene therapy into standard cancer care, ultimately affecting the overall growth and accessibility of effective treatment alternatives within the industry.

Market Trends of the Global Cancer Gene Therapy Market

The Global Cancer Gene Therapy market is witnessing a notable trend toward the increasing demand for combination therapies, driven by a rising prevalence of cancer patients seeking enhanced treatment options to improve survival rates. This shift is prompting gene therapy providers to innovate and develop new combination therapies that synergize the efficacy of various treatment modalities, thereby expanding their market presence and enhancing patient outcomes. As healthcare professionals emphasize personalized medicine and tailored treatment protocols, the focus on combination therapies in cancer gene therapy creates substantial growth opportunities for companies, positioning them at the forefront of the evolving oncology landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Cancer Gene Therapy Market Size by Type & CAGR (2026-2033)

• Market Overview
• Ex-Vivo
• In-Vivo

Global Cancer Gene Therapy Market Size by Therapy & CAGR (2026-2033)

• Market Overview
• Oncolytic Virotherapy
• Gene-Induced Immunotherapy
• Gene Transfer

Global Cancer Gene Therapy Market Size by Product & CAGR (2026-2033)

• Market Overview
• Viral Vectors
  • Adenoviruses
  • Lentiviruses
  • Retrovirus
  • Adeno Associated Virus
  • Herpes Simplex Virus
  • Vaccinia Virus
  • Other Viral Vectors
• Non-Viral Vectors
• Other Products

Global Cancer Gene Therapy Market Size by End Use & CAGR (2026-2033)

• Market Overview
• Biopharma Companies
• Research Institutes
• Other End-Users

Global Cancer Gene Therapy Market Size & CAGR (2026-2033)

• North America (Type, Therapy, Product, End Use)
  • US
  • Canada
• Europe (Type, Therapy, Product, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Therapy, Product, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Therapy, Product, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Therapy, Product, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CRISPR Therapeutics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intellia Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adaptimmune Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Autolus Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abeona Therapeutics Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations